TRX-920 is an oral delivery formulation of SN-38, the only active metabolite of Irinotecan (CPT-11). CPT-11 is an injectable chemotherapy product approved for treating colorectal and pancreatic cancer. SN-38 is ~1,000 times more potent than CPT-11 in anti-cancer activity; however, bioconversion of CPT-11 to SN-38 in cancer patients is relatively slow and limited, after an IV administration TRX-920 is designed to has the benefit of delivering sufficient SN-38 directly to the targeted tumor tissues. Oral TRX-920 is developed to reduce the burden of using high dose of CPT-11 injection without compromising overall therapeutic benefit while minimize the unwanted cytotoxic adverse effects extensively.